A new experimental drug from Novartis is making waves in the fight against prostate cancer. Early trial results show it shrinks tumors in patients, even those who stopped responding to the company's existing treatment, Pluvicto. The drug uses a different radioactive element called actinium-225, whic
Colorectal cancer is a significant health issue in the United States, ranking as the second leading cause of cancer deaths. This year, over 150, 000 new cases are expected, with nearly 53, 000 fatalities. This is a stark reminder of the urgent need for effective prevention and treatment strategies
The financial impact of cancer treatments goes far beyond the cost of the drugs themselves. Side effects from these treatments can rack up significant bills, and if these costs are not accurately measured, it can skew the overall assessment of a treatment's value. The extra costs from side effe
